Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging

Moon, Won-Jin; Choi, Jin Woo; Roh, Hong Gee; Lim, So Dug; Koh, Young-Cho

doi:10.1007/s00234-011-0947-y

Cited by 107 publications

(110 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, nodular and mixed nodular enhancement patterns and ill-defined enhancing tumor margins have been reported to be associated with MGMT methylation. 5,6,14 However, none of our conventional imaging features were significantly associated with MGMT methylation status, with p values ranging from 0.092 to 1. In accordance with our results, Gupta et al 9 also reported that there were no significant differences in imaging features between the groups after qualitative assessment of conventional MRI.…”

Section: Discussionmentioning

confidence: 82%

“…A few studies have described distinctive radiological features of glioblastoma with MGMT methylation using conventional MRI and diffusion-weighted or diffusion tensor imaging (DTI). 5,14,15 However, there are some discrepancies between the reports; some investigators have reported that the apparent diffusion coefficient (ADC) value is lower in the MGMT methylated group, 15 whereas others have reported that the ADC ratio is significantly higher in the MGMT methylated group.…”

mentioning

confidence: 99%

“…5,6,9,14 Dynamic contrast-enhanced (DCE) MRI using a contrast agent is an emerging MRI technique based on kinetic modeling of microvascular permeability that enables quantification of blood-brain barrier (BBB) breakdown. 18 Several studies have shown efficacy of permeability parameters from DCE-MRI in glioma grading.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging

Ahn

Shin

Chang³

et al. 2014

JNS

View full text Add to dashboard Cite

Object The methylation status of the methylguanine methyltransferase (MGMT) promoter has been associated with treatment response in glioblastoma. The authors aimed to assess whether MGMT methylation status can be predicted by dynamic contrast-enhanced (DCE) MRI and diffusion tensor imaging (DTI). Methods This retrospective study included 43 patients with pathologically diagnosed glioblastoma who had undergone preoperative DCE-MRI and DTI and whose MGMT methylation status was available. The imaging features were qualitatively assessed using conventional MR images. Regions of interest analyses for DCE-MRI permeability parameters (transfer constant [Ktrans], rate transfer coefficient [Kep], and volume fraction of extravascular extracellular space [Ve]) and DTI parameters (apparent diffusion coefficient [ADC] and fractional anisotropy [FA]) were performed on the enhancing solid portion of the glioblastoma. Chi-square or Mann-Whitney tests were used to evaluate relationships between MGMT methylation and imaging parameters. The authors performed receiver operating characteristic curve analysis to find the optimal cutoff value for the presence of MGMT methylation. Results MGMT methylation was not significantly associated with any imaging features on conventional MR images. Ktrans values were significantly higher in the MGMT methylated group (median 0.091 vs 0.053 min−1, p = 0.018). However, Kep, Ve, ADC, and FA were not significantly different between the 2 groups. The optimal cutoff value for the presence of MGMT methylation was Ktrans > 0.086 min−1 with an area under the curve of 0.756, a sensitivity of 56.3%, and a specificity of 85.2%. Conclusions Ktrans may serve as a potential imaging biomarker to predict MGMT methylation status preoperatively in glioblastoma; however, further investigation with a larger cohort is necessary.

show abstract

Section: Discussionmentioning

confidence: 82%

mentioning

confidence: 99%

See 1 more Smart Citation

Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging

Ahn

Shin

Chang³

et al. 2014

JNS

View full text Add to dashboard Cite

show abstract

“…85 Conversely, higher average ADC values are associated with MGMT promoter methylation. 86, 87 One study found higher rCBV in unmethylated versus methylated tumors, 88 although another study found no significant association. 86 A study of 43 GBM patients using DCE-MRIfound that MGMT methylated tumors had increased permeability (higher K trans ) compared to unmethylated tumors.…”

Section: Clinical Applications Of Advanced Mrimentioning

confidence: 99%

Conventional and advanced magnetic resonance imaging in patients with high-grade glioma

Pope¹,

Brandal²

2018

Q J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Magnetic resonance imaging is integral to the care of patients with high-grade gliomas. Anatomic detail can be acquired with conventional structural imaging, but newer approaches also add capabilities to interrogate image-derived physiologic and molecular characteristics of central nervous system neoplasms. These advanced imaging techniques are increasingly employed to generate biomarkers that better reflect tumor burden and therapy response. The following is an overview of current strategies based on advanced magnetic resonance imaging that are used in the assessment of high-grade glioma patients with an emphasis on how novel imaging biomarkers can potentially advance patient care.

show abstract

“…59 The imaging modalities used included CT (n 5 9), MRI (n 5 21, including five perfusion) and PET (n 5 6). Two studies used both CT and MR. 46,53 The number of imaging features extracted ranged from 1 to 120 with a median of 5. 11 (29%) studies used semiautomatic image feature extraction.…”

Section: Imaging Features and Extractionmentioning

confidence: 99%

Imaging genomics in cancer research: limitations and promises

Bai

Lee

Yang

et al. 2016

BJR

View full text Add to dashboard Cite

Recently, radiogenomics or imaging genomics has emerged as a novel high-throughput method of associating imaging features with genomic data. Radiogenomics has the potential to provide comprehensive intratumour, intertumour and peritumour information non-invasively. This review article summarizes the current state of radiogenomic research in tumour characterization, discusses some of its limitations and promises and projects its future directions. Semiradiogenomic studies that relate specific gene expressions to imaging features will also be briefly reviewed.

show abstract

Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging

Abstract: Preoperative imaging can predict MGMT promoter methylation status, which is of paramount importance for predicting treatment response to chemotherapy with an alkylating agent.

Cited by 107 publications

References 29 publications

Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging

Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging

Conventional and advanced magnetic resonance imaging in patients with high-grade glioma

Imaging genomics in cancer research: limitations and promises

Contact Info

Product

Resources

About